drugset / Trial / NCT05049343

Study of SAGE-904 Using a Ketamine Challenge to Evaluate Electrophysiology, Safety, Tolerability, and Pharmacokinetics in Healthy Participants

NCT05049343

Phase 1 Completed 22 enrolled Supernus Pharmaceuticals, Inc.
RandomizedCrossoverQuadruple-blindTreatment

Summary

The primary purpose of this study is to determine functional target engagement of SAGE-904 using electrophysiological paradigms before and after ketamine administration.

Timeline

Start
2021-09-21
Primary completion
2021-11-20
Completion
2021-12-03

Drugs

EvaluationDrugModalityDoseRoute
Subject SAGE-904 Unknown Oral
Background Ketamine Small molecule Intravenous

Indications

No indication recorded.